Steven Jorgensen, DO
Family Medicine · Roseburg, ORNPI 1720445380
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$896
- Otsuka America Pharmaceutical, Inc.$458
- AbbVie$440
- Pfizer$295
- GSK$260
- Novo Nordisk$253
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,054100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $896 |
| Otsuka America Pharmaceutical, Inc. | 23 | $458 |
| AbbVie | 24 | $440 |
| Pfizer | 22 | $295 |
| GSK | 14 | $260 |
| Novo Nordisk | 14 | $253 |
| Amgen(2 entities) | 11 | $197 |
| Bayer | 3 | $181 |
| Merck | 8 | $144 |
| Phathom Pharmaceuticals, Inc. | 6 | $113 |
| Exact Sciences | 4 | $82 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Lilly USA, LLC | 5 | $77 |
| Novartis | 4 | $72 |
| Sanofi Pasteur Inc. | 4 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Johnson & Johnson | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Boehringer Ingelheim | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Abbott | 2 | $36 |
| Dexcom, Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Edwards Lifesciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,066 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 122 | $150,891 |
| OzempicSemaglutide | 120 | $141,837 |
| CreonLipase/Protease/Amylase | 30 | $119,331 |
| JardianceEmpagliflozin | 100 | $100,953 |
| XareltoRivaroxaban | 62 | $66,965 |
| EliquisApixaban | 64 | $66,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $43,636 |
| FarxigaDapagliflozin Propanediol | 38 | $43,343 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $30,827 |
| VelphoroSucroferric Oxyhydroxide | 14 | $22,210 |
| TrintellixVortioxetine Hydrobromide | 29 | $17,988 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 34 | $16,111 |
| RybelsusSemaglutide | 13 | $15,546 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,321 |
| MyrbetriqMirabegron | 24 | $14,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $253 | $157,383133 claims |
| Lilly USA, LLCMounjaro | $77 | $150,891122 claims |
| AbbVieCreon, Linzess | $440 | $133,45756 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $55 | $124,699139 claims |
| PfizerEliquis, Nurtec Odt | $295 | $77,76876 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $260 | $74,463117 claims |
| Johnson & JohnsonXarelto | $59 | $66,96562 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $896 | $58,66463 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $17,98829 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $14,98824 claims |
| MerckBelsomra | $144 | $9,92823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Roseburg
- Rodney ToddRoseburg$8K
- Aimee HansenRoseburg$5K
- Layne JorgensenRoseburg$4K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.